Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
Alzheimer'S Research & Therapy|February 27, 2021
Characterization of symptoms and determinants of disease burden in dementia with Lewy bodies: DEvELOP design and baseline resultsM van de Beek, I van Steenoven, J J van der Zande, et al.
Tijdschrift Voor Gerontologie En Geriatrie|March 13, 2003
[Serum markers in relation to cognitive functioning in an aging population: results of the Maastricht Aging Study (MAAS)]C E Teunissen, M P J van Boxtel, H Bosma, et al.
Neurology|December 16, 2011
Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohortN S M Schoonenboom, F E Reesink, N A Verwey, et al.
Journal of Neurology|October 10, 2019
Olfactory and gustatory functioning and food preferences of patients with Alzheimer's disease and mild cognitive impairment compared to controls: the NUDAD projectA S Doorduijn, M A E de van der Schueren, O van de Rest, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 25, 2012
CSF neurofilament and N-acetylaspartate related brain changes in clinically isolated syndromeM Khalil, C Enzinger, C Langkammer, et al.
Neurobiology of Aging|August 21, 2003
Combination of serum markers related to several mechanisms in Alzheimer's diseaseC E Teunissen, D Lütjohann, K von Bergmann, et al.
Neuropathology and Applied Neurobiology|May 26, 2017
Brain endothelial cell expression of SPARCL-1 is specific to chronic multiple sclerosis lesions and is regulated by inflammatory mediators in vitroC Bridel, M J A Koel-Simmelink, L Peferoen, et al.
JHLT Open|March 27, 2025
Similar quality of life after balloon pulmonary angioplasty or pulmonary endarterectomy for CTEPHP Smeele, N J Braams, L Vermunt, et al.
Neurology|December 2, 2009
A consensus protocol for the standardization of cerebrospinal fluid collection and biobankingC E Teunissen, A Petzold, J L Bennett, et al.
Journal of Neurology|July 23, 2025
Reliability of serum neurofilament light and glial fibrillary acidic protein for detecting disease activity upon discontinuation of first-line disease-modifying therapy in stable multiple sclerosis (DOT-MS)W H Fung, M H J Wessels, E M E Coerver, et al.
Pageof 6